AI drug discovery
The Israel-based company is the result of AION Labs' fifth startup challenge.
Alongside generative AI, the large database has been foundational to the development of its latest AI-powered drug discovery system.
The companies will leverage Absci's AI-enabled Integrated Drug Creation platform and the pharma giant's oncology research and development expertise.
The partners will leverage IBM’s foundation model technologies to help identify antibodies designed to target and neutralize various disease-causing agents or cells.
The company will use the funds to grow its drug-discovery pipeline and clinical AI stack.
The company will use the funds to bring its AI-enabled offerings into clinical development and advance its platform and portfolio.
The round brings the company's total raise to $93 million.
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.
Also, Lunit signed multiple contracts this week to deliver its AI imaging software in Hong Kong, Mongolia, and Brazil.
Also, Edenlux is now providing AI-generated eye health reports in its mobile app.